Steven A. Rosenberg

National Institutes of Health (US)

Research Areas

Discover Papers by Steven A. Rosenberg

Access 250+ million papers and cite this researcher's work with AI assistance

Try AnswerThis Free →

H-index

219

Publications

1522

Citations

199117

i10-index

891

Publications & Citations Over Time

Top Cited Publications

Want to find and read papers by this researcher? AnswerThis gives you instant access.

Title	Year	Citations
Cancer immunotherapy: moving beyond current vaccin...	2004	2978
T cells expressing CD19 chimeric antigen receptors...	2014	2912
Cancer Regression and Autoimmunity in Patients Aft...	2002	2832
A Progress Report on the Treatment of 157 Patients...	1987	2762
A Randomized Trial of Bevacizumab, an Anti–Vascula...	2003	2705
Observations on the Systemic Administration of Aut...	1985	2669
Cancer Regression in Patients After Transfer of Ge...	2006	2606
Case Report of a Serious Adverse Event Following t...	2010	2533
Adoptive cell transfer as personalized immunothera...	2015	2507
Use of Tumor-Infiltrating Lymphocytes and Interleu...	1988	2394

Publications

1.
Cancer immunotherapy: moving beyond current vaccines
Year: 2004Citations: 2978DOI: 10.1038/nm1100
2.
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Year: 2014Citations: 2912DOI: 10.1016/s0140-6736(14)61403-3
3.
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Year: 2002Citations: 2832DOI: 10.1126/science.1076514
4.
A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
Year: 1987Citations: 2762DOI: 10.1056/nejm198704093161501
5.
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
Year: 2003Citations: 2705DOI: 10.1056/nejmoa021491
6.
Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
Year: 1985Citations: 2669DOI: 10.1056/nejm198512053132327
7.
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
Year: 2006Citations: 2606DOI: 10.1126/science.1129003
8.
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Year: 2010Citations: 2533DOI: 10.1038/mt.2010.24
9.
Adoptive cell transfer as personalized immunotherapy for human cancer
Year: 2015Citations: 2507DOI: 10.1126/science.aaa4967
10.
Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
Year: 1988Citations: 2394DOI: 10.1056/nejm198812223192527

About Steven A. Rosenberg

Steven A. Rosenberg is a researcher with 1522 publications and 199117 citations. They are affiliated with National Institutes of Health. Their research focuses on . With an h-index of 219, they are among the top researchers in their field.

Citation Distribution

Distribution of citations across publications

Research Smarter

AnswerThis uses AI to help you search, understand, and cite research from Steven A. Rosenberg and 250M+ other papers.

AI-powered research assistance
Automatic citations and references
Advanced academic writing tools

Research Area Breakdown

Publication Types

Publication type data not available

Impact Metrics Over Time

Citations per publication by year